{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T11:17:39Z","timestamp":1712834259202},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,22]]},"DOI":"10.7759\/cureus.28274","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T23:50:47Z","timestamp":1661212247000},"source":"Crossref","is-referenced-by-count":1,"title":["A Comparison of Inhaled Epoprostenol in Patients With Acute Respiratory Distress Syndrome and COVID-19-Associated Acute Respiratory Distress Syndrome"],"prefix":"10.7759","author":[{"given":"John","family":"Robinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Santarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Wilks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lelann","family":"Latu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ordessia","family":"Charran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Lalitsasivimol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyson","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ashurst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0069-0","article-title":"Acute respiratory distress syndrome","volume":"5","author":"Matthay MA","year":"2019","unstructured":"Matthay MA, Zemans RL, Zimmerman GA, et al.. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019, 5:18. 10.1038\/s41572-019-0069-0","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.5669","article-title":"Acute respiratory distress syndrome: the Berlin definition","volume":"307","author":"Ranieri VM","year":"2012","unstructured":"Ranieri VM, Rubenfeld GD, Thompson BT, et al.. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012, 307:2526-33. 10.1001\/jama.2012.5669","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpa.2020.12.011","article-title":"COVID-19-associated acute respiratory distress syndrome (CARDS): current knowledge on pathophysiology and ICU treatment - a narrative review","volume":"35","author":"Pfortmueller CA","year":"2021","unstructured":"Pfortmueller CA, Spinetti T, Urman RD, Luedi MM, Schefold JC. COVID-19-associated acute respiratory distress syndrome (CARDS): current knowledge on pathophysiology and ICU treatment - a narrative review. Best Pract Res Clin Anaesthesiol. 2021, 35:351-68. 10.1016\/j.bpa.2020.12.011","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s43044-021-00208-y","article-title":"Inhaled prostacyclin analogues in COVID-19 associated acute respiratory distress syndrome: scientific rationale","volume":"73","author":"Mulia EP","year":"2021","unstructured":"Mulia EP, Luke K. Inhaled prostacyclin analogues in COVID-19 associated acute respiratory distress syndrome: scientific rationale. Egypt Heart J. 2021, 73:82. 10.1186\/s43044-021-00208-y","journal-title":"Egypt Heart J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007733.pub3","article-title":"Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS)","volume":"7","author":"Afshari A","year":"2017","unstructured":"Afshari A, Bastholm Bille A, Allingstrup M. Aerosolized prostacyclins for acute respiratory distress syndrome (ARDS). Cochrane Database Syst Rev. 2017, 7:CD007733. 10.1002\/14651858.CD007733.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-3161","article-title":"The use of inhaled prostaglandins in patients with ARDS: a systematic review and meta-analysis","volume":"147","author":"Fuller BM","year":"2015","unstructured":"Fuller BM, Mohr NM, Skrupky L, Fowler S, Kollef MH, Carpenter CR. The use of inhaled prostaglandins in patients with ARDS: a systematic review and meta-analysis. Chest. 2015, 147:1510-22. 10.1378\/chest.14-3161","journal-title":"Chest"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2022.153990","article-title":"Inhaled pulmonary vasodilators are not associated with improved gas exchange in mechanically ventilated patients with COVID-19: a retrospective cohort study","volume":"69","author":"Lubinsky AS","year":"2022","unstructured":"Lubinsky AS, Brosnahan SB, Lehr A, et al.. Inhaled pulmonary vasodilators are not associated with improved gas exchange in mechanically ventilated patients with COVID-19: a retrospective cohort study. J Crit Care. 2022, 69:153990. 10.1016\/j.jcrc.2022.153990","journal-title":"J Crit Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/21548331.2022.2047310","article-title":"Evaluation of aerosolized epoprostenol for hypoxemia in non-intubated patients with coronavirus disease 2019","volume":"50","author":"Kataria V","year":"2022","unstructured":"Kataria V, Ryman K, Tsai-Nguyen G, Wakwaya Y, Modrykamien A. Evaluation of aerosolized epoprostenol for hypoxemia in non-intubated patients with coronavirus disease 2019. Hosp Pract (1995). 2022, 50:118-23. 10.1080\/21548331.2022.2047310","journal-title":"Hosp Pract (1995)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/0885066620976525","article-title":"Responsiveness of inhaled epoprostenol in respiratory failure due to COVID-19","volume":"36","author":"Sonti R","year":"2021","unstructured":"Sonti R, Pike CW, Cobb N. Responsiveness of inhaled epoprostenol in respiratory failure due to COVID-19. J Intensive Care Med. 2021, 36:327-33. 10.1177\/0885066620976525","journal-title":"J Intensive Care Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000307","article-title":"Effects of inhaled epoprostenol and prone positioning in intubated coronavirus disease 2019 patients with refractory hypoxemia","volume":"2","author":"Li J","year":"2020","unstructured":"Li J, Fink JB, Augustynovich AE, Mirza S, Kallet RH, Dhand R. Effects of inhaled epoprostenol and prone positioning in intubated coronavirus disease 2019 patients with refractory hypoxemia. Crit Care Explor. 2020, 2:e0307. 10.1097\/CCE.0000000000000307","journal-title":"Crit Care Explor"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06022-5","article-title":"Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)","volume":"46","author":"Alhazzani W","year":"2020","unstructured":"Alhazzani W, M\u00f8ller MH, Arabi YM, et al.. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020, 46:854-87. 10.1007\/s00134-020-06022-5","journal-title":"Intensive Care Med"},{"key":"ref12","unstructured":"Care of critically ill adults with COVID-19. (2022). Accessed. June 23, 2022: https:\/\/www.covid19treatmentguidelines.nih.gov\/management\/critical-care-for-adults\/summary-recommendations\/."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.07.015","article-title":"A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension","volume":"104","author":"Mubarak KK","year":"2010","unstructured":"Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010, 104:9-21. 10.1016\/j.rmed.2009.07.015","journal-title":"Respir Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/2045894020970369","article-title":"Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19","volume":"10","author":"Franco V","year":"2020","unstructured":"Franco V, Bradley EA, Badagliacca R, et al.. Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19. Pulm Circ. 2020, 10:2045894020970369. 10.1177\/2045894020970369","journal-title":"Pulm Circ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214103","article-title":"Prone positioning in severe acute respiratory distress syndrome","volume":"368","author":"Gu\u00e9rin C","year":"2013","unstructured":"Gu\u00e9rin C, Reignier J, Richard JC, et al.. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013, 368:2159-68. 10.1056\/NEJMoa1214103","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211069182","article-title":"Evaluation of continuous inhaled epoprostenol in the treatment of acute respiratory distress syndrome, including patients with SARS-CoV-2 infection","author":"Niss HL","year":"2022","unstructured":"Niss HL, Mohamed A, Berry TP, Saettele TM, Haines MM, Thomas EL. Evaluation of continuous inhaled epoprostenol in the treatment of acute respiratory distress syndrome, including patients with SARS-CoV-2 infection. Ann Pharmacother. 2022, 10600280211069182. 10.1177\/10600280211069182","journal-title":"Ann Pharmacother"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.04271","article-title":"A comprehensive review of prone position in ARDS","volume":"60","author":"Kallet RH","year":"2015","unstructured":"Kallet RH. A comprehensive review of prone position in ARDS. Respir Care. 2015, 60:1660-87. 10.4187\/respcare.04271","journal-title":"Respir Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/104481-a-comparison-of-inhaled-epoprostenol-in-patients-with-acute-respiratory-distress-syndrome-and-covid-19-associated-acute-respiratory-distress-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:30Z","timestamp":1707507570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/104481-a-comparison-of-inhaled-epoprostenol-in-patients-with-acute-respiratory-distress-syndrome-and-covid-19-associated-acute-respiratory-distress-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.28274","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,22]]}}}